Clinical trial
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
NCT00451321
Study timeline
Study start (actual)2006-07-31Date precision: day
Registry last updated2017-11-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 1unresolved
Interventions
OtelixizumabDRUG
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Juvenile Diabetes Research Foundationcollaborator
Mapped research locations
ChicagoIllinois, United States1BaltimoreMaryland, United States1TorontoOntario, Canada1San AntonioTexas, United States1BirminghamAlabama, United States1Washington D.C.District of Columbia, United States1MinneapolisMinnesota, United States1JacksonvilleFlorida, United States1AuroraColorado, United States1OmahaNebraska, United States1Walnut CreekCalifornia, United States1WorcesterMassachusetts, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00451321 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.